Current stock page

Catalysts

TNGX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

TNGXTango Therapeutics, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$25.50+$0.65 (+2.62%)

Latest quote

  • Momentum
    60
  • Value
    —
  • Quality
    73
  • Risk resilience
    38
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 4, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 61/100

Momentum 60/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment -10.56%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 60/100AIQ Edge 10/10 Sector Leader
Beat rate
25%
2 of 8 reported periods
Average surprise
+145.3%
Across covered historical reports
Latest result
-10.5%
Nov 9, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 9, 2026—-$0.35-$0.39-10.5%$3.28M—
Aug 10, 2026—-$0.32-$0.37-16.6%$1.56M—
May 13, 2026—-$0.31-$0.32-2.0%$578.09K—
Mar 5, 2026—-$0.31-$0.29+6.5%$500.4K—
Nov 4, 2025—$0.01$0.13+1200.0%$556K$53.81M
Aug 5, 2025—-$0.35-$0.35+0.0%$6.41M$3.18M
May 12, 2025—-$0.34-$0.36-5.9%$6.36M$5.39M
Feb 27, 2025—-$0.32-$0.35-9.4%$8.02M$4.12M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
12
Buy
1
Hold
12-month analyst target
$56.00
+119.61% versus current price
Based on 13 analyst observations. Targets are estimates, not predictions.
Low target
$45.00
+76.47% vs latest price
Average target
$56.00
+119.61% vs latest price
High target
$68.00
+166.67% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 4, 2027

Next known earnings or reporting date.

EPS estimate-$0.39

Current analyst expectation for the upcoming report.

Revenue estimate$636.73K

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score60

Where event reaction would show up first.

AIQ score61/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
13
Average target
$56.00
Target upside
119.61%
Target range
$45.00 - $68.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
1
Neutral
2
Negative
2
gurufocus.com · Nov 9, 2026

Tango Therapeutics (TNGX) Reports Q3 Loss Amid Elevated Price-to-Sales Valuation

On November 09, 2026, Tango Therapeutics Inc (NASDAQ: TNGX) announced a third-quarter GAAP loss of $0.39 per share, totaling a net loss of $68.4 million for the

seekingalpha.com · Oct 28, 2026

Tango Therapeutics: The ESMO Sell-Off Missed What The Daraxonrasib Dose Is Saying

Tango Therapeutics offers an 82% ORR and notable durability in MTAP-deleted/RAS-mutant pancreatic cancer. Read more on TNGX stock here.

insidermonkey.com · Oct 28, 2026

Tango Therapeutics (TNGX) vs. CRSP and SMMT: Can Vopimetostat Turn Promising Cancer Data Into an 89% Upside?

Is TNGX a good stock to buy? We came across a bullish thesis on Tango Therapeutics, Inc. on BioEquity Watch’s Substack.

seekingalpha.com · Oct 27, 2026

Tango Therapeutics, Inc. (TNGX) Discusses Updated Vopimetastat Combination Data and Registration Strategy in Pancreatic Cancer - Slideshow (NASDAQ:TNGX) 2026-10-27

2026-10-27. The following slide deck was published by Tango Therapeutics, Inc.

zacks.com · Sep 10, 2026

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Open full news and sentiment

TNGX Catalysts FAQ

What are the next catalysts for TNGX stock?

TNGX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move TNGX stock?

Upcoming events that could move TNGX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could TNGX's next earnings report affect the stock?

TNGX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive TNGX stock higher?

TNGX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt TNGX stock?

TNGX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.